InsidersTradesSigma
Follow the *ST双成 stock price and the full directors' dealings record of the company, a publicly traded company based in China. Shares are quoted on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, *ST双成 has published 7 insider filings. Market capitalisation: €4bn. The latest transaction was filed on 4 August 2026 (Sale). Among the most active insiders: 姚忠. Every trade is free.
7
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€558,981
7 ops.
Sell Volume
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,095 of 29,063 companies
41.7
score / 100
Value26
Quality58
FCF yld0.5%
Earn yld0.5%
EV/EBITDA56.0x
ROE10.0%
Gross mgn55%
Net mgn6.9%
Debt/EBITDA3.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 August 2026
Declarations7 total
10,000 sharesA股XSHESZSE:173000006004796900
240,000 sharesA股XSHESZSE:173000005937704350
7 of 7 declarations
关于 *ST双成
*ST双成 是一家在 XSHE 市场上市的公司，专注于医疗保健和制药领域。该公司致力于创新药物和疗法的开发与生产。